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Objectives: Salivary gland ultrasonography (SGUS) is increasingly applied for the
management of primary Sjögren’s syndrome (pSS). This study aims to: (i) compare the
reliability between two SGUS scores; (ii) test the reliability among sonographers with
different levels of experience.
Methods: In the reliability exercise, two four-grade semi-quantitative SGUS scoring
systems, namely De Vita et al. and OMERACT, were tested. The sonographers involved
in work-package 7 of the HarmonicSS project from nine countries in Europe were invited
to participate. Different levels of sonographers were identified on the basis of their SGUS
experience and of the knowledge of the tested scores. A dedicated atlas was used as
support for SGUS scoring.
Results: Twenty sonographers participated in the two rounds of the reliability exercise.
The intra-rater reliability for both scores was almost perfect, with a Light’s kappa of 0.86
for the De Vita et al. score and 0.87 for the OMERACT score. The inter-rater reliability
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for the De Vita et al. and the OMERACT score was substantial with Light’s Kappa of
0.75 and 0.77, respectively. Furthermore, no significant difference was noticed among
sonographers with different levels of experience.
Conclusion: The two tested SGUS scores are reliable for the evaluation of major
salivary glands in pSS, and even less-expert sonographers could be reliable if
adequately instructed.
Keywords: Sjögren’s syndrome, scoring system, classification criteria, reliability exercise, salivary gland
ultrasonography
INTRODUCTION
Primary Sjögren’s syndrome (pSS) is a systemic autoimmune
and lymphoproliferative disease, mainly involving the salivary
glands (SGs) (1). In pSS, the SGs inflammatory process
ultimately results in glandular structural damage (2, 3).
Active glandular lesions are characterized by inflammation and
lymphoproliferation, with varying degrees of glandular damage
by fibrosis, fatty accumulation, and loss of acinar and ductal
parenchyma (4–6). These pathological abnormalities, for whose
characterization SG biopsy is the gold standard technique, lead
to the typical glandular inhomogeneity detected by salivary
gland ultrasonography (SGUS), with hypo/anechoic areas and
hyperechoic bands (7–10). So far, parenchymal inhomogeneity
proved to be the main sonographic feature to build SGUS scores
in pSS (7, 8, 11). In 1992, De Vita et al. firstly developed a
comprehensive sonographic score of major SGs in pSS defining,
by means of a discriminant analysis, inhomogeneity as the main
SGUS abnormality associated with pSS; the developed semi-
quantitative score ranged from 0 to 3 in each gland, from
normal-appearing morphology to severe inhomogeneity (7).
Several scoring systems have been proposed subsequently, and
most of them used glandular inhomogeneity as the key SGUS
abnormality. In addition, several clinicians now routinely use
SGUS to assess patients with suspected or established pSS (9, 10,
12). However, even if many authors strongly believe that SGUS is
relevant for the management of pSS, definite recommendations
are still lacking, and this technique is not yet part of the
classification criteria for pSS. This is mainly due to: (i) the
absence of consensus on elementary SGUS lesions and scoring
when pSS classification criteria were set up (12); (ii) the evidence
of significant intra- and inter-rater disagreement (12–14); (iii)
the use of old pSS cohorts for validation of pSS classification
criteria, when SGUS was not yet fully developed (15). In order to
overcome these issues, the Outcome Measure in Rheumatology
(OMERACT) working group on the use of ultrasonography in
pSS recently generated, after a three-round Delphi process, the
definitions for the SGUS elementary lesions in pSS, and the
Abbreviations: ACR-EULAR, American College of Rheumatology/European
League Against Rheumatism; GRAAS, Guidelines for Reporting Reliability
and Agreement Studies; NU-E, non-users and experts; NU-NE, non-users
and non-experts; OMERACT, Outcome Measures in Rheumatology Clinical
Trials; OMI, outcome measure instruments; PG, parotid gland; pSS, primary
Sjögren’s syndrome; SGs, salivary glands; SGUS, salivary gland ultrasound; SMG,
submandibular gland; U-E, user and experts; U-NE, users and non-experts.
scanning procedure (16). Lastly, the same OMERACT group
developed a four-grade SGUS score, which showed excellent
intra-rater reliability and a good inter-rater reliability between
experts (16). By the possible addition of SGUS as a new criterion,
the 2016 ACR-EULAR criteria for the classification of pSSmay be
ameliorated in sensitivity without modifying the specificity (17).
On the other hand, very few data exist to support the reliability
of SGUS in pSS, and all the published studies involved only
experts and well-trained sonographers. Therefore, it definitely
remains to be investigated how reliability varies along with the
observer training level and experience, and this still represents
the major obstacle for a wider acceptance of SGUS in pSS
evaluation (13).
Furthermore, the images from previous studies were not
publicly available, making rather difficult for subsequent studies
to reproduce and/or to objectively compare their findings.
Accordingly, the leading pSS experts (35 partners from
13 countries) have recently started the HarmonicSS (http://
harmonicss.eu) initiative to envelop independently reported
cohorts and metacentric data, including SGUS in a dedicated
Workpackage (WP), namely WP7. This study was created within
the HarmonicSS initiative, and it is preliminary to further studies
on the application of artificial intelligence in SGUS. At the
current stage of the initiative, this study aims to: (i) evaluate the
reliability among sonographers with different levels of expertise
in SGUS; (ii) compare the reliability performance between two
different semi-quantitative SGUS scores, widely used and easy to
perform, being the “extremes” in the year of publication (i.e., the
scores by De Vita et al., 1992, and by OMERACT, 2019); (iii)
provide a data set that will be publicly available, to serve as a
standardized benchmark for further studies.
MATERIALS AND METHODS
The Guidelines for Reporting Reliability and Agreement
Studies (GRAAS) were followed for the preparation of the
manuscript (18).
Salivary Gland Ultrasound Scores
A simple, semi-quantitative 0–3 SGUS scoring system was
recently selected by a systematic review and meta-analysis as
more appropriate for diagnostic purposes in terms of specificity
and heterogeneity in pSS, with respect to the other scoring
systems available (e.g., 0–16 and 0–48) (19). One of the aims
of the work-package 7 (WP7) of the HarmonicSS project is to
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develop and improve the role of SGUS for pSS management.
Participants and coordinators of WP7 agreed to use two
four-grade semi-quantitative scoring systems, namely De Vita
et al. score (7) and OMERACT score (16), for the assessment
of major SGs morphology in pSS patients enrolled in the
HarmonicSS project.
The score by De Vita et al. is the long-standing available
in the literature in pSS, is easy-to-perform, and includes both
hypo/anechoic areas and hyperechoic bands as the main
sonographic features to define parenchymal SG inhomogeneity,
while in the OMERACT score parenchymal inhomogeneity
is supported only by the presence of hypo/anechoic areas.
The De Vita et al. score comprises: grade 0, normal-appearing
parenchyma; grade 1, mild inhomogeneity with isolated and
small hypo/anechoic areas, without hyperechoic bands; grade 2,
evident inhomogeneity with multiple scattered hypo/anechoic
areas and/or few hyperechoic bands; grade 3, severe/gross
inhomogeneity due to large and confluent hypo/anechoic areas
and/or diffuse hyperechoic bands (Figure 1). In this exercise,
as well as in the recent studies where the De Vita et al. score
was applied (20–22), the grade 1 was better specified, since
the term of “mild inhomogeneity” was initially included, as a
diffuse or localized micro-areolar structure. The OMERACT
score is the most recent one, proposed in 2019 according
to guidelines for selecting outcome measure instruments
(OMI) (23) and it is defined as follows: grade 0, normal-
appearing SG parenchyma; grade 1, minimal change: mild
inhomogeneity without hypo/anechoic areas; grade 2, moderate
change: moderate inhomogeneity with focal hypo/anechoic
areas; grade 3, severe change: diffuse inhomogeneity
with hypo/anechoic areas occupying the entire gland
surface (Figure 1).
Participants
Twenty-seven sonographers involved in the WP7 of the
HarmonicSS project (https://www.harmonicss.eu/the-project/
project-structure/) from nine countries in Europe (Austria,
France, Germany, Italy, Norway, Serbia, Slovenia, The
Netherlands, and United Kingdom) were invited to participate.
The years of experience in SGUS, the number of pSS patients
evaluated per year, and scores usually used in clinical practice
were collected for each participant. Sonographers with at least
6 years of experience in SGUS were identified as experts, while
the user definition was applied in those who already applied
the De Vita et al. and/or OMERACT scores in clinical practice
or for research purposes. Four different levels of sonographers
were then identified as follows: user and experts (U-E group),
non-users and experts (NU-E group), users and non-experts (U-
NE), non-users, and non-experts (NU-NE group). A dedicated
SGUS atlas was sent to all participants, with general SGUS issues,
and with definitions and examples for each grade of glandular
inhomogeneity for both scores.
Reliability Exercise and HarmonicSS Data
Set
A pool of 225 sonographic static images (83 normal-appearing
images, 42 images with mild inhomogeneity, 47 images
FIGURE 1 | Ultrasound images of parotid glands in the two four-grade
semi-quantitative scoring system: (A) De Vita et al. score grade 0; (B) De Vita
et al. score grade 1; (C) De Vita et al. score grade 2; (D) De Vita et al. score
grade 3; (E) OMERACT score grade 0; (F) OMERACT score grade 1; (G)
OMERACT score grade 2; (H) OMERACT score grade 3.
with moderate inhomogeneity, and 53 images with severe
inhomogeneity) of major SGs [114 parotid glands (PGs) and
111 sub-mandibular glands (SMGs)], from 150 patients with
suspected pSS or definite pSS, was independently scored
in two rounds. The sonographic images were previously
collected and de-identified from the database of four
rheumatologists involved in the exercise (AZ, AH, VM,
ODL) and were different from those presented in the atlas.
Four different ultrasound machines were used to store
images, i.e., Samsung RS85, Philips Epiq, GE Logiq E9, and
ESAOTE MyLab70. For both scoring rounds, each observer
was provided with an anonymized and uniquely randomized
data set in order to ensure that scorings performed in this
study could be not influenced with others’ scorings. The
reliability exercise was carried out remotely by using the
HarmonicSS web-based platform (https://private.harmonicss.
eu). For each round, the participants had to apply the De
Vita et al. score and the OMERACT score for each of the 225
images. The described data set, together with accompanying
script files and instructions for their usage, are publicly
available on the GitHub repository (https://github.com/
ArsoVukicevic/Assessment-of-pSS-fromSGUSimages/tree/
master/3%20HarmonicSS%20benchmark%20dataset) that will
be further managed by the HarmonicSS group and authors of
this study.
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Statistical Analysis
Inter-rater reliability was assessed by using kappa statistics and
computing the linear and squared weighted and unweighted
kappa coefficient (Fleiss-Cohen weights) for each pair of raters
for both scores considered. In the analyses the weighted kappa
(i.e., linear and squared kappa), in addition to unweighted kappa,
was performed since the use of weighting schemes allows to
take into account the closeness of agreement between categories.
The weights are presented in Supplementary Table 1. The mean,
median, 1st and 3rd quartile, minimum (min), and maximum
(max) kappa values were calculated. Then Light’s kappa was
considered as the mean kappa value. To assess intra-rater
reliability, we computed the linear and squared weighted and
unweighted kappa coefficients between two readings by each
rater for both scores. We then computed Light’s kappa (mean of
intra-rater kappa values), median, 1st and 3rd quartile, minimum
(min), and maximum (max) kappa values. The bootstrap
percentile method was used to compute the 95% CI of every
Light’s, Fleiss and Cohen kappa. Furthermore, we converted








De Vita et al. score
0–3 weighted (squared)
0.86 0.79 0.95 0.84–0.89
De Vita et al. score
normal vs. pathological (0 vs. 1)
0.80 0.67 0.95 0.76–0.84
OMERACT score
0–3 weighted (squared)
0.87 0.81 0.95 0.85–0.90
OMERACT score
normal vs. pathological (0 vs. 1)
0.81 0.59 0.95 0.76–0.85









De Vita et al. score
0–3 weighted (squared)
0.76 0.50 0.92 0.72–0.79
De Vita et al. score
normal vs. pathological (0 vs. 1)
0.68 0.37 0.86 0.63–0.72
OMERACT score
0–3 weighted (squared)
0.77 0.57 0.93 0.74–0.80
OMERACT score
normal vs. pathological (0 vs. 1)
0.71 0.42 0.92 0.65–0.75
II Round
De Vita et al. score
0–3 weighted (squared)
0.73 0.45 0.91 0.70–0.76
De Vita et al. score
normal vs. pathological (0 vs. 1)
0.67 0.29 0.89 0.62–0.71
OMERACT score
0–3 weighted (squared)
0.74 0.58 0.93 0.71–0.77
OMERACT score
normal vs. pathological (0 vs. 1)
0.70 0.49 0.91 0.65–0.74
every 0–3 score database in 0–1 score database considering
scores 0 and 1 as normal-appearing scores and converted to 0;
whereas scores 2 and 3 were held as pathological scores and
were converted to score 1. Every analysis was repeated in the 0–1
score database. We stratified squared weighted kappa coefficients
by levels of SGUS experience and the knowledge of the tested
scoring systems. We obtained kappa for four levels combining
experience and use information: U-E, U-NE, NU-E, and NU-NE.
The results were then compared to evaluate the overlap between
95% confidence intervals. Kappa coefficients were interpreted
according to Landis and Koch (24). Kappa values of 0–0.20
were considered slight, 0.21–0.40 fair, 0.41–0.60 moderate, 0.61–
0.80 substantial, and 0.81–1.00 almost perfect. All statistical
analyses were carried out using R version 3.6.2 (R Foundation
for Statistical Computing, Vienna, Austria). For clarity, only
weighted kappa are displayed in the text and tables; however,
full statistical results are available in the Supplementary Material
results and in the repository.
RESULTS
Participants
Twenty out of 27 invited sonographers from eight countries
in Europe (Austria, France, Germany, Italy, Norway, Serbia,
Slovenia, and The Netherlands) participated in the two rounds of
the reliability exercise. Seventeen out of 20 were rheumatologists,
two were radiologists, and one was a specialist in oral medicine.
Their experience with SGUS was 8.75 (± 5.97) years, with a mean
number of pSS patients evaluated by SGUS per year of 127.6 (±
108.43). Thirteen out of 20 (65%) sonographers were experts,
and 14/20 (70%) were users. The mean SGUS use was 11.8 (±
TABLE 3 | Inter-rater reliability in the first and second round: comparison between









PGs–De Vita et al. score 0–3
Kappa weighted (squared)
0.81* 0.60 0.94 0.77–0.85*
SMGs–De Vita et al. score 0–3
Kappa weighted (squared)
0.68 0.35 0.91 0.62–0.73
PGs–OMERACT score 0–3
Kappa weighted (squared)
0.81* 0.62 0.94 0.78–0.85*
SMGs–OMERACT score 0–3
Kappa weighted (squared)
0.70 0.50 0.92 0.65–0.75
II Round
PGs–De Vita et al. score 0–3
Kappa weighted (squared)
0.77 0.54 0.91 0.73–0.80
SMGs–De Vita et al. score 0–3
Kappa weighted (squared)
0.68 0.30 0.92 0.62–0.73
PGs–OMERACT score 0–3
Kappa weighted (squared)
0.76* 0.62 0.93 0.74–0.82*
SMGs–OMERACT score 0–3
Kappa weighted (squared)
0.69 0.45 0.93 0.63–0.73
PGs, Parotid Glands; SMGs, Submandibular glands.
*Significant difference between the reliability of PGs and SMGs.
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5.0) years for experts and 3.0 (± 1.5) years for non-experts (p
< 0.001). Nine out of twenty (45%) sonographers were U-E,
5/20 (25%) were U-NE, 4/20 (20%) were NU-E, and 2/20 (10%)
were NU-NE.
Participants Scores
The mean De Vita et al. score and OMERACT score of the first
round is reported in Supplementary Figure 1. The mean De Vita
et al. score was 1.14 (± 1.10) for U-E, 1.33 (± 1.12) for U-NE,
1.31 (± 1.10) for NU-E, and 1.45 (± 1.08) for NU-NE. The
mean OMERACT score was 1.28 (± 1.16) for U-E, 1.41 (± 1.07)
for U-NE, 1.41 (± 1.13) for NU-E, and 1.80 (± 1.08) for NU-
NE. The mean OMERACT score in NU-NE was significantly
higher compared with U-E group (p< 0.05). No other significant
differences among groups were present.
Reliability Exercise
Intra-Rater Reliability
The intra-rater reliability for the De Vita et al. and the
OMERACT score was almost perfect with a Light’s Kappa
of 0.86 (0.79–0.95; 95% CI 0.84–0.89) and 0.87 (range 0.81–
0.95; 95% CI 0.85–0.90), respectively (Table 1). High levels of
reliability were also reached when comparing normal-appearing
scores vs. pathological scores, achieving a Light’s Kappa of
0.80 for the De Vita et al. (0.67–0.95; 95% CI 0.76–0.84) and
0.81 for the OMERACT score (0.59–0.95; 95% CI 0.76–0.85)
(Table 1). Unweighted kappa and weighted linear kappa are
presented in Supplementary Table 2. No significant differences
were found between the intra-rater reliability of PGs and SMGs
(Supplementary Table 3).










De Vita et al. score
0–3 weighted
(squared)
U-E group 0.87 0.82 0.91 0.85–0.89
U-NE group 0.84 0.79 0.88 0.82–0.86
NU-E group 0.88 0.81 0.95 0.85–0.92
NU-NE group 0.87 0.87 0.87 0.87–0.87




U-E group 0.82 0.74 0.87 0.79–0.85
U-NE group 0.74 0.67 0.81 0.71–0.77
NU-E group 0.85 0.78 0.95 0.81–0.89




U-E group 0.87 0.83 0.93 0.86–0.90
U-NE group 0.85 0.82 0.86 0.84–0.85
NU-E group 0.91 0.84 0.95 0.87–0.92





U-E group 0.83 0.77 0.92 0.81–0.86
U-NE group 0.78 0.75 0.82 0.76–0.80
NU-E group 0.86 0.81 0.95 0.82–0.89
NU-NE group 0.68 0.59 0.76 0.63–0.73
U-E group, user and experts; U-NE group, users and non-experts; NU-E group, non-users
and experts; NU-NE group, non-users and non-experts.
Inter-Rater Reliability
The inter-rater reliability for the De Vita et al. and the
OMERACT score was substantial with Light’s Kappa of 0.76
(0.50–0.92; 95% CI 0.72–0.79) and 0.77 (0.57–0.93; 95% CI
0.74–0.80), respectively (Table 2). Comparing normal-appearing
scores (0–1) vs. pathological scores (2–3), the Light’s kappa value
was substantial both for the De Vita et al. score (kappa value:
0.68; range 0.37–0.86; 95% CI 0.63–0.72) and the OMERACT
score (kappa value: 0.71; range 0.42–0.92; 95% CI 0.65–0.75)
(Table 2). Similar results were obtained in the second round
of the exercise (Table 2). Unweighted kappa and weighted
linear kappa of the inter-rater reliability are presented in
Supplementary Tables 4, 5. Higher inter-rater reliability was
achieved in PGs compared to SMGs (Table 3).
Intra-Rater Reliability Among Sonographers With
Different Levels of Experience and Use of SGUS
Scores
The intra-rater reliability for the De Vita et al. score and the
OMERACT score was almost perfect in all groups. For the De
Vita et al. score, the Light’s kappa ranged from 0.84 for U-NE
(0.79–0.88; 95% CI 0.82–0.86) to 0.88 for NU-E (0.81–0.95; 95%
CI 0.85–0.92). For the OMERACT score the Light’s kappa ranged
from 0.85 for U-NE (0.82–0.86; 95% CI 0.84–0.85) to 0.91 for
NU-E (0.84–0.95; 95% CI 0.87–0.92) (Table 4).
Inter-Rater Reliability Among Sonographers With
Different Levels of Experience and Use of SGUS
Scores
The Light’s kappa of the four groups showed a substantial level of
inter-reliability for the De Vita et al. and the OMERACT scores
TABLE 5 | First and second round inter-rater reliability among different groups of
sonographers.
Inter-rater reliability among groups Light’s kappa 95% CI
I round
De Vita et al. score 0–3
weighted (squared)
U-E group 0.78 0.74–0.81
U-NE group 0.71 0.66–0.75
NU-E group 0.77 0.72–0.80
NU-NE group 0.79 0.75–0.84
II round De Vita et al.
score
0–3 weighted (squared)
U-E group 0.74 0.70–0.87
U-NE group 0.70 0.66–0.75
NU-E group 0.75 0.70–0.79




U-E group 0.78 0.75–0.81
U-NE group 0.78 0.74–0.81
NU-E group 0.78 0.74–0.82




U-E group 0.73 0.69–0.77
U-NE group 0.72 0.67–0.75
NU-E group 0.78 0.74–0.81
NU-NE group 0.85 0.81–0.89
U-E group, user and experts; U-NE group, users and non-experts; NU-E group, non-users
and experts; NU-NE group, non-users and non-experts.
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in both rounds (Table 5). For the De Vita et al. score, the Light’s
kappa of the first round ranged from 0.71 for U-NE (0.66–0.75)
to 0.79 for NU-NE (0.75–0.84). For OMERACT score the Light’s
kappa of the first round ranged from 0.78 for U-E (0.75–0.81),
U-NE (0.74–0.81), and NU-E (0.74–0.82) to 0.79 for NU-NE
(0.73–0.84) (Table 5).
DISCUSSION
In this web-based reliability exercise, two different semi-
quantitative SGUS scores for pSS proved to be reliable for the
sonographic evaluation of the major SGs. In addition, regardless
of the level of the sonographer’s experience, an almost perfect
intra-rater reliability, and substantial inter-rater reliability, were
reached. Finally, images and data of the present study will be
publicly available to facilitate further investigations.
Few previous studies evaluated the reproducibility of SGUS in
pSS, usually with few experts and with variable results (8, 9, 11).
Recently the authors of the OMERACT score of SGUS in pSS
highlighted a good reliability for their score among 25 experts
(16). This study involved an equally relevant number of raters,
but also with different levels of expertise. In order to use SGUS
as an OMI and as an item for pSS classification, its reliability
must be tested, and it is recommended that the weighted kappa
should be >0.7 (25). Over the past years, SGUS has received
a growing interest as it is a non-invasive and easily performed
technique for the management of pSS (26). Furthermore, in
clinical practice, SGUS semi-quantitative scores are easy to apply
and have a good discriminatory power between pathological and
normal-appearing major SGs (7, 8, 10). This exercise tested the
application of two different, easy-to-apply, 0–3 semi-quantitative
scores for SGUS, namely the ones developed by De Vita et al. in
1992 and by OMERACT in 2019. The former includes features
of both inflammation (i.e., hypo/anechoic areas) and damage
(i.e., hyperechoic bands), whereas the latter, including mainly
features of glandular inflammation, was built following the recent
OMI recommendations. In this study, both the scores showed
an almost perfect intra-rater reliability and substantial inter-
rater reliability among 20 sonographers with different levels
of experience and knowledge of SGUS scores. The number of
involved sonographers and the stratification of the sonographers,
based on their experience, are the main strengths of this study.
In this reliability exercise, being a non-expert and/or a non-user
did not significantly impact the level of agreement among raters.
Importantly, however, a support for SGUS evaluation and scoring
was given to raters, by means of a dedicated atlas of images. We
did not investigate whether the less expert sonographers were
those mainly using the atlas or not, since it was poorly feasible.
Further studies, in any case, should better define the optimal way
to support SGUS rating in pSS. The automatic scoring of SGUS
by image segmentation and artificial intelligence is also being
evaluated in HarmonicSS.
As already highlighted by the OMERACT study, the reliability
among PGs and SMGs was different also in this study, and worse
in the SMGs than in the PGs for both the tested scores (16).
This could be in part expected since a mild inhomogeneity (e.g.,
grade 1 for both the scores) of the SMGs can be difficult to be
differentiated from the normal gland. The main limitation of
the study was the absence of a patient-based exercise; ideally,
reliability testing should also be performed in the clinical
setting with the patient, and not with the sole images. In this
scenario, practical sonographic skills could make the difference
among groups with different levels of experience, but a high
number of sonographers are needed, making this type of exercise
challenging to plan. Furthermore, the presence of only two
raters in the NU-NE group could be another study limitation.
In this multi-center reliability exercise, groups with an equal
number of participants could not be defined a priori, since the
choice of sonographers was made by each center involved in the
European project.
In conclusion, this study focused on SGUS reliability, i.e.,
the main limit for a wider use of SGUS in pSS. Both the tested
SGUS scores proved to be reliable for the evaluation of pSS
patients and this reinforces and supports the reliability of SGUS
as highlighted by the OMERACT study (16). Furthermore, in this
study the agreement was independent of the years of experience
of sonographers and of their previous use of the tested scores.
Overall, in our opinion, major evidence to further encourage the
use of SGUS in pSS in the next future is provided.
PATIENT AND PUBLIC INVOLVMENT IN
RESEARCH
EULAR PARE and SSF–Sjögren’s Syndrome Foundation have
an advisory role in HarmonicSS and will continuously monitor
and evaluate the project (outcomes) in terms of impact to
patients. Also, EULAR PARE and SSF have a major role in
the dissemination of the results to patient associations and the
public. https://www.harmonicss.eu/patients-advisory-group/.
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